Prolia Shortage: What Providers and Prescribers Need to Know in 2026

Prolia (denosumab) is not on the FDA Drug Shortage Database as of 2026 — but prescribers across the country are still fielding calls from patients who can't get their injection on time. The problem isn't a manufacturing shortage; it's a system-level disruption driven by biosimilar formulary switches, prior authorization delays, specialty distribution bottlenecks, and practice-level ordering failures. This guide is for physicians, NPs, PAs, and office staff who manage Prolia patients.

Why Patients Are Missing Doses in 2026

The core challenge: Prolia is a specialty biologic that doesn't sit on pharmacy shelves. It must be ordered through a specialty distributor, shipped to your office, and administered in a controlled setting. Any disruption in this chain — insurance, distribution, or scheduling — can leave patients overdue for their injection.

The Biosimilar Formulary Switch: What Prescribers Need to Know

As of 2026, nine FDA-approved biosimilars to Prolia are available. Insurers — including multiple Medicare Advantage plans — have begun preferring or requiring biosimilars over brand Prolia on their formularies. Key developments:

• Some UnitedHealthcare Medicare Advantage plans replaced Prolia with Jubbonti and Wyost as interchangeable biosimilars as of September 1, 2025.
• Independence Blue Cross implemented Jubbonti as a preferred alternative to Prolia as of September 2025.
• Amgen's own biosimilar, Stoboclo, is one of the approved denosumab biosimilars. Biosimilars are therapeutically equivalent and interchangeable — no dose adjustment is needed.

Clinical implication: If your office has been ordering brand Prolia but a patient's insurance has switched to requiring a biosimilar, claims may be denied and the injection delayed. Audit your active Prolia patients' insurance plans before each scheduled injection and confirm which product is covered.

Prior Authorization: A Common Source of Delays

Prior authorization for Prolia is commonly required by commercial plans and Medicare Part D. Authorization often expires after 12 months. If your clinical staff doesn't track renewal dates, patients may arrive for their injection only to find coverage has lapsed. Recommended workflow:

1. Flag patients whose prior auth expires within 60 days and initiate renewal early.
2. Verify benefits and confirm authorization before ordering the drug from your distributor.
3. If step therapy is required, document failed bisphosphonate trials in clinical notes to support the PA.

Clinical Risks of Missed Prolia Doses: The Rebound Fracture Danger

Unlike bisphosphonates, denosumab has no residual skeletal effect after stopping. When Prolia is discontinued — or even delayed — bone resorption rebounds rapidly to levels above pre-treatment baseline. This rebound is most dangerous at the vertebral level, with case reports of multiple spontaneous vertebral fractures within months of stopping denosumab without transitioning to another antiresorptive agent.

The FDA's prescribing information for Prolia explicitly states: "Multiple vertebral fractures (MVF) have been reported following Prolia discontinuation. Patients should be transitioned to another antiresorptive agent if Prolia is discontinued." Providers should counsel all Prolia patients about the importance of on-time dosing and never stopping without a transition plan.

Managing the Transition: When Prolia Must Be Stopped

If a patient must stop Prolia for any reason — cost, side effects, contraindication, or supply — the recommended approach is:

• Administer zoledronic acid (Reclast, 5 mg IV) approximately 6 months after the last Prolia dose to suppress the rebound bone resorption surge.
• For patients who cannot tolerate IV zoledronic acid, consider oral bisphosphonate therapy initiated at the 6-month post-Prolia window.
• Monitor serum CTX (bone resorption marker) to assess the magnitude of rebound if clinically warranted.

Updated Boxed Warning: Hypocalcemia in Advanced CKD

In January 2024, the FDA added a boxed warning to Prolia for severe hypocalcemia in patients with advanced chronic kidney disease (CKD), particularly those on dialysis or with CKD-mineral and bone disorder (CKD-MBD). Severe hypocalcemia in this population resulted in hospitalizations, life-threatening events, and deaths. Before initiating Prolia in patients with advanced CKD: evaluate for CKD-MBD, ensure involvement of a nephrologist or CKD-MBD specialist, correct pre-existing hypocalcemia, and supplement calcium 1,000 mg/day and vitamin D 400 IU/day.

How medfinder Supports Provider Practices

When your office can't source Prolia in time for a patient, the worst outcome is a missed dose. medfinder for providers helps your care team quickly identify which nearby infusion centers or practices can administer Prolia or a denosumab biosimilar, so you can redirect patients safely — not just reschedule them.

Related resource: How to Help Your Patients Find Prolia in Stock: A Provider's Guide.